EMBC Embecta Corp. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$3.38

Period return

-7.67 (-69.41%)

Volume

1.4M

2026-06-05O $3.4 H $3.48 L $3.37 C $3.38MA5 $3.38MA20 $3.28MA60 $6.86MA120 $8.98

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 19.LowSELL19 days ago
B of A Securities: Underperform
US analyst rating / recommendation change.
2026. 05. 06.LowHOLDlast month
Mizuho: Neutral
US analyst rating / recommendation change.
2026. 05. 06.MediumHOLDlast month
BTIG: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $4 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies
HQ: Parsippany, NJ, United States
Fiscal year end: —
Employees: 1,850
IPO date: —

View details →